Clinical data evaluation after matrix-associated autologous chondrocyte transplantation: a retrospective study
ESSKA Academy. TIEFENBÖCK T. 11/08/19; 284419; epESMA-02 Topic: E6 - Autologous chondrocyte transplantation (ACT)
Dr. Thomas, Manfred TIEFENBÖCK
Dr. Thomas, Manfred TIEFENBÖCK
Login now to access Regular content available to all registered users.

You can access free regular educational content on the ESSKA Academy by registering as an 'ESSKA Academy User’ here

Access to Premium content is currently a membership benefit.

Click here to join ESSKA or renew your membership.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Clinical data evaluation after matrix-associated autologous chondrocyte transplantation: a retrospective study

ePoster - epESMA-02

Topic: Sports Trauma

Binder H.1, Aldrian S.2, Zak L.2, Tiefenböck T.2, Marlovits S.2, Albrecht C.2
1Medical University of Vienna, Department of Orthopedics and Trauma-Surgery, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria

Introduction: Matrix-associated autologous chondrocyte transplantation (MACT) has been an effective tool of tissue engineering for large, full thickness cartilage lesions for years. Despite the wide variety of available scaffolds, only few are in clinical use today. The aim of this study is to compare four of the most commonly used implants regarding their clinical outcome.
Objectives: To determine if there is a difference in short term clinical outcome between four different MACT types.
Aims: The aim of this study is to compare four of the most commonly used implants retrospectively.
Methods: 88 Patients with full-thickness chondral lesions of the tibiofemoral joint, who underwent MACT, were included in this study. Clinical examination was performed preoperatively, as well as 24 months after transplantation. Clinical outcomes were evaluated using the IKDC, Brittberg, Lysholm and VAS score.
The Kruskal-Wallis test by ranks was applied to compare the clinical scores of the different transplant types.
Results: A total of 88 patients (mean age: 45a, mean BMI: 25), who suffered from tibiofemoral lesions were included. The average defect size of the tibiofemoral joint compartment was 4.28 cm2. 11 patients (12.6%) underwent transplantation with Chondro- Guide (MACI), 40 patients (46.0%) with Hyallograft (HYAFF), 21 patients (24.1%) with Cares and 15 patients (17.2%) with Novocart. Patients improved from a mean IKDC score of 35.71 (±6,44) preoperative to 75.26 (±18.36)after 24 months in the Hyallograft group, 35.94 (±10.29) to 71.57(±16.31) in the Chondro-Guide (MACI) group, 37.06 (±5.42) to 71.49 (±6.76) in the Novocart group and 45.05 (±15.83) to 70.33 (±19.65) in the Cares group. Similar improvement were seen in VAS and Brittberg scores. Two years postoperative there were no significant differences regarding the outcome.
Conclusion: Our data demonstrated that MACT regardless of the used implants resulted in good clinical improvement 2 years after transplantation for tibiofemoral defect localizations.
Clinical data evaluation after matrix-associated autologous chondrocyte transplantation: a retrospective study

ePoster - epESMA-02

Topic: Sports Trauma

Binder H.1, Aldrian S.2, Zak L.2, Tiefenböck T.2, Marlovits S.2, Albrecht C.2
1Medical University of Vienna, Department of Orthopedics and Trauma-Surgery, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria

Introduction: Matrix-associated autologous chondrocyte transplantation (MACT) has been an effective tool of tissue engineering for large, full thickness cartilage lesions for years. Despite the wide variety of available scaffolds, only few are in clinical use today. The aim of this study is to compare four of the most commonly used implants regarding their clinical outcome.
Objectives: To determine if there is a difference in short term clinical outcome between four different MACT types.
Aims: The aim of this study is to compare four of the most commonly used implants retrospectively.
Methods: 88 Patients with full-thickness chondral lesions of the tibiofemoral joint, who underwent MACT, were included in this study. Clinical examination was performed preoperatively, as well as 24 months after transplantation. Clinical outcomes were evaluated using the IKDC, Brittberg, Lysholm and VAS score.
The Kruskal-Wallis test by ranks was applied to compare the clinical scores of the different transplant types.
Results: A total of 88 patients (mean age: 45a, mean BMI: 25), who suffered from tibiofemoral lesions were included. The average defect size of the tibiofemoral joint compartment was 4.28 cm2. 11 patients (12.6%) underwent transplantation with Chondro- Guide (MACI), 40 patients (46.0%) with Hyallograft (HYAFF), 21 patients (24.1%) with Cares and 15 patients (17.2%) with Novocart. Patients improved from a mean IKDC score of 35.71 (±6,44) preoperative to 75.26 (±18.36)after 24 months in the Hyallograft group, 35.94 (±10.29) to 71.57(±16.31) in the Chondro-Guide (MACI) group, 37.06 (±5.42) to 71.49 (±6.76) in the Novocart group and 45.05 (±15.83) to 70.33 (±19.65) in the Cares group. Similar improvement were seen in VAS and Brittberg scores. Two years postoperative there were no significant differences regarding the outcome.
Conclusion: Our data demonstrated that MACT regardless of the used implants resulted in good clinical improvement 2 years after transplantation for tibiofemoral defect localizations.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies